Imfinzi EU Bladder Cancer Filing On Back Burner As AZ Focuses On Lung

The CHMP decided against an accelerated review of Imfinzi in both bladder and lung cancer but unlike in the case of NSCLC, AstraZeneca has not filed for the former indication.